Bausch (BHC) Reports Q3 Earnings: What Key Metrics Have to Say

Impact · against what's priced in

Bausch Health is likely to see a positive price adjustment following a substantial beat on both top and bottom lines for Q3 2026. The EPS surprise of 63.89% and revenue growth of 9.7% suggest a fundamental performance acceleration beyond current analyst expectations.

BHC+0.70

No priced-in read yet

In context

Bausch Health delivered a significant beat with Q3 EPS of $1.77 against a $1.08 estimate and revenue of $2.94 billion, exceeding the $2.75 billion consensus.

Read from the article alone

• revenue▲18%
• earnings▲3%
• eps
• healthcare
• fundamental analysis
• BHC
• pharmaceuticals

Top 2 movers · tap to explore